{"id":917090,"date":"2025-12-07T18:23:27","date_gmt":"2025-12-07T23:23:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/"},"modified":"2025-12-07T18:23:27","modified_gmt":"2025-12-07T23:23:27","slug":"structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/","title":{"rendered":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, Dec.  07, 2025  (GLOBE NEWSWIRE) &#8212; Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company\u2019s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day.<\/p>\n<p>To access the live webcast, please visit the Investor Relations page of the company\u2019s website at https:\/\/ir.structuretx.com\/events-presentations\/events. To access the call by phone, participants should visit this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hIArqxRAWFbfNc5KoR-luruoQ-ZC9wYp9gaIGUf6z4NwQwSqpDFR9By9Wh-JeP0_KeF_ROV4dxKg--cSKdXhfez9akQUMt75q8kzPwWEegpZEdka1xvTzm3rznR_nGwSwGmsACzgc2VYqlVcQ0ARTcNNQdoAAqhoqTnRidSiWJ4=\" rel=\"nofollow\" target=\"_blank\">link<\/a> to receive dial-in details. The webcast will be made available for replay on the company&#8217;s website beginning approximately two hours after the live event. The replay of the webcast will be available for 90 days.<\/p>\n<p>\n        <strong>About Structure Therapeutics<\/strong><br \/>\n        <br \/>Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world.\u00a0For additional information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2iB72Nn914BVs7EPrX45vV6A9B8Gh3tueqPYL6__Kz9BOJrkFvAosgK650btmFbPevavm7CSZlAAQLVZg-8yfLlMpVfNouv3nTQeShnK-4Jy9PbB0VCh1GwNZSSaljM4eOxtrK0AM1gPv7yi9ujZVTjq0nw021ZWoOjnXna_1UmoNjwJd0XZphUMWVwpF2CrLEfVFvlWsuW4XaCj0ZAFG-S8agoAdWW-7qrk2LQ1FTYO9bOYDUF0KAan-Yn61E402X2K0khyr5wlyX58VftoJA==\" rel=\"nofollow\" target=\"_blank\">www.structuretx.com<\/a>.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Danielle Keatley<br \/>Structure Therapeutics Inc.<br \/>ir@structuretx.com<\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Dan Budwick<br \/>1AB<br \/>Dan@1abmedia.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjRiN2YwYzMtMGI4Ny00YzAwLTg5NDMtMWZmZWQ1ODA1ZTRmLTEyNTc1OTEtMjAyNS0xMi0wNy1lbg==\/tiny\/Structure-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) &#8212; Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company\u2019s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company\u2019s website at https:\/\/ir.structuretx.com\/events-presentations\/events. To access the call by phone, participants should visit this link to receive &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917090","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) &#8212; Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company\u2019s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company\u2019s website at https:\/\/ir.structuretx.com\/events-presentations\/events. To access the call by phone, participants should visit this link to receive &hellip; Continue reading &quot;Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-07T23:23:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025\",\"datePublished\":\"2025-12-07T23:23:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/\"},\"wordCount\":275,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/\",\"name\":\"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=\",\"datePublished\":\"2025-12-07T23:23:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/","og_locale":"en_US","og_type":"article","og_title":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - Market Newsdesk","og_description":"SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) &#8212; Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company\u2019s once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company\u2019s website at https:\/\/ir.structuretx.com\/events-presentations\/events. To access the call by phone, participants should visit this link to receive &hellip; Continue reading \"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-07T23:23:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025","datePublished":"2025-12-07T23:23:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/"},"wordCount":275,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/","name":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=","datePublished":"2025-12-07T23:23:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODIxMiM3MzEwMjMyIzIyNDYwMzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-to-report-data-from-access-clinical-program-of-oral-small-molecule-glp-1-receptor-agonist-aleniglipron-on-december-8-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917090"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917090\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}